Form 8-K Revance Therapeutics, For: Oct 15
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- S&P 500 volatile in choppy trading; Mideast deal, SpaceX debut in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil nears two-month lows on reports of imminent US-Iran peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
Revance Therapeutic (RVNC) PT Lowered to $25 at Needham & Company
October 18, 2021 6:41 AM EDTNeedham & Company analyst Serge Belanger lowered the price target on Revance Therapeutic (NASDAQ: RVNC) to $25.00 (from $45.00) while maintaining a Buy rating.
The analyst commented, "FDA issued a CRL for the Daxi BLA due to deficiencies related to the FDA's inspection of the Revance... More
